MHRA-100324-PIP01-21-M01 (update)

Key Facts

Active Substance
Active Substance:
  • Loncastuximab tesirine
Invented Name
  • Zynlonta
  • Zynlonta
  • Zynlonta
  • Zynlonta
  • Zynlonta
PIP Number MHRA-100324-PIP01-21-M01 (update)
Pharmaceutical form(s)
Pharmaceutical form(s):
  • Powder for concentrate for solution for infusion
Therapeutic area
Therapeutic area:
  • Oncology
Conditions / Indications
Conditions / Indications:
  • Treatment of mature B-cell neoplasms
Route(s) of administration
Route(s) of administration:
  • Intravenous use
PIP applicant
  • Swedish Orphan Biovitrum AB
  • Country Sweden
  • Tel +4686972000
  • Email info@sobi.com
Decision Type
Decision Type
PM: decision on the application for modification of an agreed paediatric investigation plan.
Compliance Check
Compliance Check
No
Compliance Check Decision Date
Compliance Check Procedure Number

Decision Document

Decision Document Decision Document on a Paediatric Investigation Plan (PIP):LONCASTUXIMAB TESIRINE.pdf
Published Date 28/10/2024